Relationship between macular pigment and visual acuity in eyes with early age-related macular degeneration

Acta Ophthalmologica

Volumn 91, Issue 4, 2013, Pages

  Puell, María C ^a   Palomo Alvarez, Catalina ^a   Barrio, Ana R ^a   Gómez Sanz, Fernando J ^b   Pérez Carrasco, María Jesús ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b Universidad Francisco de Vitoria   (Spain)

Author keywords

age related macular degeneration; macular pigment optical density; visual acuity

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LUMINANCE; MALE; OPTICAL DENSITY; PHOTOMETRY; PHOTOPIC VISION; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA LUTEA; VISION; VISION TEST; VISUAL ACUITY;

AGED; CELL COUNT; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MACULA LUTEA; MACULAR DEGENERATION; MALE; MIDDLE AGED; PHOTOMETRY; RETINAL PIGMENT EPITHELIUM; VISION TESTS; VISUAL ACUITY;

EID: 84878448087     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.12067     Document Type: Article

References (55)

1. Abadi RV, &, Pantazidou M, (1996): Low contrast letter acuity in age-related maculopathy. Ophthalmic Physiol Opt 16: 455-459.
2. Anstis S, &, Cavanagh P, (1983): A minimum motion technique for judging equiluminance. In:, Mollon J, &, Sharpe L, (eds). Colour Vision: Psychophysics and Physiology. London: Academic Press 66-77.
3. Bahrami H, Melia M, &, Dagnelie G, (2006): Lutein supplementation in retinitis pigmentosa: PC-based vision assessment in a randomized double-masked placebo-controlled clinical trial [NCT00029289]. BMC Ophthalmol 6: 23.
4. Barbur JL, Konstantakopoulou E, Rodriguez-Carmona M, Harlow JA, Robson AG, &, Moreland JD, (2010): The Macular Assessment Profile test-a new VDU-based technique for measuring the spatial distribution of the macular pigment, lens density and rapid flicker sensitivity. Ophthalmic Physiol Opt 30: 470-483.
5. Bartlett HE, &, Eperjesi F, (2008): A randomised controlled trial investigating the effect of lutein and antioxidant dietary supplementation on visual function in healthy eyes. Clin Nutr 27: 218-227.
6. Bartlett H, &, Eperjesi F, (2011): Apparent motion photometry: evaluation and reliability of a novel method for the measurement of macular pigment. Br J Ophthalmol 95: 662-665.
7. Bartlett H, Stainer L, Singh S, Eperjesi F, &, Howells O, (2010): Clinical evaluation of the MPS 9000 macular pigment screener. Br J Ophthalmol 94: 753-756.
8. Beatty S, Murray IJ, Henson DB, Carden D, Koh H, &, Boulton ME, (2001): Macular pigment and risk for age-related macular degeneration in subjects from a Northern European population. Invest Ophthalmol Vis Sci 42: 439-446.
9. Berendschot TT, Willemse-Assink JJ, Bastiaanse M, de Jong PT, &, van Norren D, (2002): Macular pigment and melanin in age-related maculopathy in a general population. Invest Ophthalmol Vis Sci 43: 1928-1932.
10. Bernstein PS, Zhao D-Y, Wintch SW, Ermakov IV, McClane RW, &, Gellermann W, (2002): Resonance Raman measurement of macular carotenoids in normal subjects and in age-related macular degeneration patients. Ophthalmology 109: 1780-1787.
11. Bernstein PS, Delori FC, Richer S, van Kuijk FJ, &, Wenzel AJ, (2010): The value of measurement of macular carotenoid pigment optical densities and distributions in age-related macular degeneration and other retinal disorders. Vision Res 50: 716-728.
12. Bird AC, Bressler NM, Bressler SB, et al., (1995): An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 39: 367-374.
13. Bone RA, Landrum JT, &, Tarsis SL, (1985): Preliminary identification of the human macular pigment. Vision Res 25: 1531-1535.
14. Bone RA, Landrum JT, Mayne ST, Gomez CM, Tibor SE, &, Twaroska EE, (2001): Macular pigment in donor eyes with and without AMD: a case-control study. Invest Ophthalmol Vis Sci 42: 235-240.
15. Cangemi FE, (2007): TOZAL Study: an open case control study of an oral antioxidant and omega-3 supplement for dry AMD. BMC Ophthalmol 7: 3.
16. Chylack LT Jr, Wolfe JK, Singer DM, et al., (1993): The Lens Opacities Classification System III. The Longitudinal Study of Cataract Study Group. Arch Ophthalmol 111: 831-836.
17. Ciulla TA, Hammond BR Jr, Yung CW, &, Pratt LM, (2001): Macular pigment optical density before and after cataract extraction. Invest Ophthalmol Vis Sci 42: 1338-1341.
18. Delcourt C, Carriere I, Delage M, Barberger-Gateau P, &, Schalch W, (2006): Plasma lutein and zeaxanthin and other carotenoids as modifiable risk factors for age-related maculopathy and cataract: the POLA Study. Invest Ophthalmol Vis Sci 47: 2329-2335.
19. Dietzel M, Zeimer M, Heimes B, Claes B, Pauleikhoff D, &, Hense HW, (2011): Determinants of macular pigment optical density and its relation to age-related maculopathy: results from the Muenster Aging and Retina Study (MARS). Invest Ophthalmol Vis Sci 52: 3452-3457.
20. Falsini B, Fadda A, Iarossi G, Piccardi M, Canu D, Minnella A, Serrao S, &, Scullica L, (2000): Retinal sensitivity to flicker modulation: reduced by early age-related maculopathy. Invest Ophthalmol Vis Sci 41: 1498-1506.
21. Hagen S, Krebs I, Glittenberg C, &, Binder S, (2010): Repeated measures of macular pigment optical density to test reproducibility of heterochromatic flicker photometry. Acta Ophthalmol 88: 207-211.
22. Hammond BR Jr, Wooten BR, &, Snodderly DM, (1998): Preservation of visual sensitivity of older subjects: association with macular pigment density. Invest Ophthalmol Vis Sci 39: 397-406.
23. Jahn C, Wustemeyer H, Brinkmann C, Trautmann S, Mossner A, &, Wolf S, (2005): Macular pigment density in age-related maculopathy. Graefes Arch Clin Exp Ophthalmol 243: 222-227.
24. Kanis MJ, Berendschot TT, &, van Norren D, (2007): Influence of macular pigment and melanin on incident early AMD in a white population. Graefes Arch Clin Exp Ophthalmol 245: 767-773.
25. Kanis MJ, Wisse RPL, Berendschot T, van de Kraats J, &, van Norren D, (2008): Foveal cone-photoreceptor integrity in aging macula disorder. Invest Ophthalmol Vis Sci 49: 2077-2081.
26. Kinkelder R, van der Veen R, Verbaak F, Faber D, van Leeuwen T, &, Berendschot T, (2011): Macular pigment optical density measurements: evaluation of a device using heterochromatic flicker photometry. Eye 25: 105-112.
27. Kleiner RC, Enger C, Alexander MF, &, Fine SL, (1988): Contrast sensitivity in age-related macular degeneration. Arch Ophthalmol 106: 55-57.
28. Kvansakul J, Rodriguez-Carmona M, Edgar DF, Barker FM, Kopcke W, Schalch W, &, Barbur JL, (2006): Supplementation with the carotenoids lutein or zeaxanthin improves human visual performance. Ophthalmic Physiol Opt 26: 362-371.
29. LaRowe TL, Mares JA, Snodderly DM, Klein ML, Wooten BR, Chappell R, & CMPS Group (2008): Macular pigment density and age-related maculopathy in the Carotenoids in Age-Related Eye Disease Study. An ancillary study of the women's health initiative. Ophthalmology 115: 876-883.e871.
30. Li B, Vachali P, &, Bernstein PS, (2010): Human ocular carotenoid-binding proteins. Photochem Photobiol Sci 9: 1418-1425.
31. Loane E, Kelliher C, Beatty S, &, Nolan JM, (2008): The rationale and evidence base for a protective role of macular pigment in age-related maculopathy. Br J Ophthalmol 92: 1163-1168.
32. Loughman J, Akkali MC, Beatty S, et al., (2010): The relationship between macular pigment and visual performance. Vision Res 50: 1249-1256.
33. Loughman J, Scanlon G, Nolan JM, O'Dwyer V, &, Beatty S, (2012): An evaluation of a novel instrument for measuring macular pigment optical density: the MPS 9000. Acta Ophthalmol 90: e90-97.
34. Lovie-Kitchin JE, (1989): High contrast and low contrast visual acuity in age related macular degeneration. Clin Exp Optom 72: 79-83.
35. Moreland JD, Robson AG, &, Kulikowski JJ, (2001): Macular pigment assessment using a colour monitor. Color Res Appl 26: 261-265.
36. Nolan JM, Stringham JM, Beatty S, &, Snodderly DM, (2008): Spatial profile of macular pigment and its relationship to foveal architecture. Invest Ophthalmol Vis Sci 49: 2134-2142.
37. Nolan JM, O'Reilly P, Loughman J, Stack J, Loane E, Connolly E, &, Beatty S, (2009): Augmentation of macular pigment following implantation of blue light-filtering intraocular lenses at the time of cataract surgery. Invest Ophthalmol Vis Sci 50: 4777-4785.
38. Nolan JM, Loughman J, Akkali MC, Stack J, Scanlon G, Davison P, &, Beatty S, (2011): The impact of macular pigment augmentation on visual performance in normal subjects: COMPASS. Vision Res 51: 459-469.
39. Obana A, Hiramitsu T, Gohto Y, et al., (2008): Macular carotenoid levels of normal subjects and age-related maculopathy patients in a Japanese population. Ophthalmology 115: 147-157.
40. Olmedilla B, Granado F, Blanco I, &, Vaquero M, (2003): Lutein, but not alpha-tocopherol, supplementation improves visual function in patients with age-related cataracts: a 2-y double-blind, placebo-controlled pilot study. Nutrition 19: 21-24.
41. Pérez-Carrasco MJ, Barrio A, Palomo-Alvarez C, &, Puell M, (2009): Repeatability in the measurement of macular pigment optical density using the Metropsis Test. Acta Ophthalmol 87.
42. Phipps JA, Dang TM, Vingrys AJ, &, Guymer RH, (2004): Flicker perimetry losses in age-related macular degeneration. Invest Ophthalmol Vis Sci 45: 3355-3360.
43. Raphael S, &, MacLeod DI, (2011): Mesopic luminance assessed with minimum motion photometry. J Vis 11: 14, 1- 21.
44. Reading VM, &, Weale RA, (1974): Macular pigment and chromatic aberration. J Opt Soc Am 64: 231-234.
45. Renzi LM, &, Hammond BR, (2010): The effect of macular pigment on heterochromatic luminance contrast. Exp Eye Res 91: 896-900.
46. Richer S, Stiles W, Statkute L, et al., (2004): Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry 75: 216-230.
47. Snodderly DM, (1995): Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins. Am J Clin Nutr 62: 1448S-1461S.
48. Snodderly DM, Auran JD, &, Delori FC, (1984): The macular pigment. II. Spatial distribution in primate retinas. Invest Ophthalmol Vis Sci 25: 674-685.
49. Snodderly D, Mares J, Wooten B, Oxton L, Gruber M, &, Ficek T, (2004): Macular pigment measurement by heterochromatic flicker photometry in older subjects: the carotenoids and age-related eye disease study. Invest Ophthalmol Vis Sci 45: 531-538.
50. Stringham JM, &, Hammond BR, (2008): Macular pigment and visual performance under glare conditions. Optom Vis Sci 85: 82-88.
51. Stringham JM, Garcia PV, Smith PA, McLin LN, &, Foutch BK, (2011): Macular pigment and visual performance in glare: benefits for photostress recovery, disability glare, and visual discomfort. Invest Ophthalmol Vis Sci 52: 7406-7415.
52. The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the Age-Related Eye Disease Study Report Number 6 (2001): Am J Ophthalmol 132: 668-681.
53. Tsika C, Tsilimbaris MK, Makridaki M, Kontadakis G, Plainis S, &, Moschandreas J, (2011): Assessment of macular pigment optical density (MPOD) in patients with unilateral wet age-related macular degeneration (AMD). Acta Ophthalmol 89: e573-e578.
54. Weigert G, Kaya S, Pemp B, et al., (2011): Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 52: 8174-8178.
55. Wooten B, Hammond B, Land R, &, Snodderly D, (1999): A practical method for measuring macular pigment optical density. Invest Ophthalmol Vis Sci 40: 2481-2489.